Oslo University Hospital, Ullevål, formerly Ullevål University Hospital in Oslo, Norway is the largest of the four main campuses of Oslo University Hospital. It was opened in 1887, and was an independent hospital owned by Oslo municipality and then by the state until it became part of Oslo University Hospital in 2009.

There are 1,200 beds in Oslo Universitetssykehus, Ullevål.

During the past decade, Oslo Universitetssykehus, Ullevål conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 2 clinical trials were completed, i.e. on average, 16.7% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 1 clinical trials were completed. i.e. 16.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Oslo Universitetssykehus, Ullevål" #1 sponsor was "Pfizer" with 4 trials, followed by "Oslo University Hospital" with 2 trials sponsored, "Clovis Oncology, Inc." with 1 trials sponsored, "Diakonhjemmet Hospital" with 1 trials sponsored and "Helse Møre og Romsdal HF" with 1 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Oslo Universitetssykehus, Ullevål" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "Oslo University Hospital" with 2 trials as a collaborator, "Barrow Neurological Institute" with 1 trials as a collaborator and "Merck Sharp & Dohme LLC" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Oslo Universitetssykehus, Ullevål" are "Multiple Myeloma" (3 trials), "Anterior Cruciate Ligament" (1 trials), "Aortic Valve Stenosis" (1 trials), "Cancer" (1 trials) and "Cancer of the Esophagus" (1 trials). Many other conditions were trialed in "Oslo Universitetssykehus, Ullevål" in a lesser frequency.

Most popular intervention types in "Oslo Universitetssykehus, Ullevål" are "Drug" (13 trials), "Other" (3 trials), "Device" (2 trials), "Biological" (1 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Capecitabine" (2 trials), "Cetuximab" (2 trials), "Elranatamab" (2 trials) and "Encorafenib" (2 trials). Other intervention names were less common.

The vast majority of trials in "Oslo Universitetssykehus, Ullevål" are 21 trials for "All" genders.

Currently, there are NaN active trials in "Oslo Universitetssykehus, Ullevål". undefined are not yet recruiting, 6 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Oslo Universitetssykehus, Ullevål, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Oslo Universitetssykehus, Ullevål, 2 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 4 trials that are defined as “Not Applicable".